匹多莫德、地塞米松联合阿奇霉素治疗支原体肺炎患儿的临床疗效

Clinical efficacy of pidotimod, dexamethasone combined with azithromycin in the treatment of children with mycoplasma pneumonia

目的探析匹多莫德、地塞米松联合阿奇霉素治疗支原体肺炎患儿的临床疗效。方法60例支原体肺炎患儿,通过随机数字表方式分为对照组和观察组,每组30例。对照组患儿应用阿奇霉素治疗,观察组患儿在对照组治疗基础上应用匹多莫德、地塞米松治疗。比较两组临床疗效、预后情况(不良反应发生情况以及复发情况)。结果观察组治疗总有效率93.33%高于对照组的73.33%,差异具有统计学意义(P<0.05)。观察组不良反应发生率3.33%、复发率0均低于对照组的20.00%、16.67%,差异均具有统计学意义(P<0.05)。结论对支原体肺炎患儿应用匹多莫德、地塞米松联合阿奇霉素方案可有效控制病情发展,安全性高,降低复发率,值得推广。

Objective To discuss the clinical efficacy of pidotimod,dexamethasone combined with azithromycin in the treatment of children with mycoplasma pneumonia.Methods A total of 60 children with mycoplasma pneumonia were randomly divided into control group and observation group by random numerical table,with 30 cases in each group.Children in the control group were treated with azithromycin,and children in the observation group were treated with pidotimod and dexamethasone on the basis of the control group.The clinical efficacy and prognosis(the occurrence of adverse reactions and recurrence)were compared between the two groups.Results The total effective rate 93.33%of the observation group was higher than 73.33%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 3.33%and the recurrence rate 0 in the observation group were both lower than 20.00%and 16.67%in the control group,and the differences were statistically significant(P<0.05).Conclusion The application of pidotimod,dexamethasone combined with azithromycin in children with mycoplasma pneumonia can effectively control the development of the disease,with high safety,and can reduce the recurrence rate,which is worthy of promotion.